Comparative efficacy and safety of endoscopic treatments for gastric varices: a systematic review and network meta-analysis.

EndoscopyMay 19, 2026 (epub)
Clinical ResearchGastroenterology

Mattia Brigida, Stefano Francesco Crinò, Abdulrahman Alfadda et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and network meta-analysis evaluated the efficacy and safety of various endoscopic treatments for gastric varices in 760 patients across 10 randomized controlled trials. EUS-guided cyanoacrylate injection and EUS-guided coil+cyanoacrylate injection demonstrated significantly lower rebleeding rates compared to direct endoscopic cyanoacrylate injection, with risk ratios of 0.39 and 0.15, respectively.

Key findings

  • EUS-guided cyanoacrylate injection reduced rebleeding rates (RR 0.39, 95%CI 0.27-0.58) compared to direct endoscopic cyanoacrylate injection.
  • EUS-guided coil+cyanoacrylate injection showed even lower rebleeding rates (RR 0.15, 95%CI 0.03-0.90).
  • EUS-guided cyanoacrylate injection had a lower adverse event rate (RR 0.59, 95%CI 0.48-0.72) than endoscopic cyanoacrylate injection.
  • Large-volume band ligation and thrombin injection also had lower adverse event rates compared to endoscopic cyanoacrylate injection.

Why it matters

Understanding the comparative efficacy and safety of endoscopic treatments for gastric varices is crucial for optimizing patient management and reducing complications associated with rebleeding.

What to keep in mind

The quality of evidence was very low, indicating a need for further randomized controlled trials to confirm findings.

Source

Published in Endoscopy. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.